Targeting protein kinases for tumor therapy

Onkologie

Volumn 24, Issue 4, 2001, Pages 346-355

  Sachsenmaier, Christoph ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Clinical trials; Inhibitors; Protein kinases; Receptor tyrosine kinases; Serine threonine kinases; Targets; Tumor therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 7 HYDROXYSTAUROSPORINE; ALPHA INTERFERON; ANGIOZYME; CEP 701; CETUXIMAB; CISPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE; CYTARABINE; DOCETAXEL; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GENE EXPRESSION MODULATOR 231; GENISTEIN; IMATINIB; IRINOTECAN; ISIS 3521; MIDOSTAURIN; NERVE GROWTH FACTOR; PACLITAXEL; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; SEMAXANIB; SOMATOMEDIN C; TRASTUZUMAB; UNINDEXED DRUG; VATALANIB;

CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; DIMERIZATION; DRUG EFFECT; DRUG INDICATION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; MUTATION; NONHUMAN; ONCOGENE; PROGNOSIS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0035743340     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055106     Document Type: Review

References (135)

1. Abelson murine leukemia virus protein is phosphorylated in vitro to form phosphotyrosine
2. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine
3. The Croonian lecture 1997: The phosphorylation of proteins on tyrosine: Its role in cell growth and disease
4. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas
5. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase
6. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6
7. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases
8. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
9. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
10. Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines
11. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with NEU oncogene
12. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase
13. Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells
14. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis
15. Clinical spectrum of fibroblast growth factor mutations
16. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
17. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
18. GDNF signalling through the Ret receptor tyrosine kinase
19. Frequent activation of ret protooncogene by fusion with activating gene in papillary thyroid carcinomas
20. The met oncogene: From detection by transfection to transmembrane receptor for hepatocyte growth factor
21. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
22. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas
23. A novel germ line juxtamembrane met mutation in human gastric cancer
24. High frequency of c-Met expression in gastric cancers producing alpha-fetoprotein
25. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer
26. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
27. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma
28. Effect of a null mutation of the insulin-like growth factor factor 1 receptor gene on growth and transformation of mouse embryo fibroblasts
29. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
30. The trk proto-oncogene product: A signal transducing receptor for nerve growth factor
31. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor
32. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
33. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma
34. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
35. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
36. Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases
37. The novel activation of ABL by fusion to an ets-related gene, TEL
38. Analysis of the murine Dtk gene identifies conservation of genomic structure within a new receptor tyrosine kinase subfamily
39. Mouse mammary tumors express elevated levels of RNA encoding the murine homology of SKY, a putative receptor tyrosine kinase
40. Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3
41. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene
42. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
43. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
44. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
45. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
46. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
47. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway
48. Vascular endothelial growth factor and the angiopoietins: Working together to build a better blood vessel
49. The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia
50. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis
51. c-Yes tyrosine kinase activity in human colon carcinoma
52. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma
53. Activating src mutation in a subset of advanced human colon cancers
54. Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients
55. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model
56. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
57. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia
58. A single ataxia telangiectasia gene with a product similar to PI-3 kinase
59. Cancer risk and the ATM gene: A continuing debate
60. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation
61. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks
62. Interaction between ATM protein and c-Abl in response to DNA damage
63. Circular chromosome formation in a fission yeast mutant defective in two ATM homologues
64. The yeast TEL1 gene partially substitutes for human ATM in suppressing hyperrecombination, radiation-induced apoptosis and telomere shortening in A-T cells
65. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase
66. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction
67. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity
68. Molecular analysis of the h-warts/LATS1 gene in human breast cancer
69. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines
70. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
71. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
72. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast
73. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics
74. Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
75. Types of cyclic AMP binding proteins in human breast cancers
76. Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer
77. The role of Raf kinases in development and growth of tumors
78. The raf oncogene is associated with a radiation-resistant human laryngeal cancer
79. Molecular cloning of an activated human oncogene, homologous to v-raf, from primary stomach cancer
80. Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: Shift of the c-raf 1 locus
81. Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis
82. From amplification to gene in thyroid cancer: A high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization
83. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
84. A phase II study of STI571 in adult patients with philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
85. A phase II study to determine the safety and antileukemic effects of STI571 in adult patients with philadelphia chromosome positive acute leukemias
86. SU6668 is a potent anti-angiogenic and antitumor agent that induces regression of established tumors
87. Herceptin (trastuzamab) in advanced breast cancer
88. Monoclonal antibody therapy for solid tumors
89. Issues in the development of gene therapy: Preclinical experiments in E1A gene delivery
90. Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias
91. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of the Swiss group for clinical cancer research (SAKK)
92. Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines
93. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)(p12;q12)
94. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
95. Multiple endocrine neoplasia type 2 and RET: From neoplasia to neurogenesis
96. The ret/PTC oncogene in papillary thyroid carcinoma
97. ERBB2 oncogene in human breast cancer and its clinical significance
98. Role of neurotrophin-trk interactions in oncology: The anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models
99. ETK2 receptor tyrosine kinase promotes survival of factor-dependent FDC- P1 progenitor cells
100. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
101. VEGF receptor signaling in tumor angiogenesis
102. A cellular oncogene is translocated to the philadelphia chromosome in chronic myelocytic leukaemia
103. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells
104. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia
105. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer
106. Cyclin D1 in parathyroid disease
107. Antisense DNA-targeting protein kinase A-RIA subunit: A novel approach to cancer treatment
108. A phase II, multi-center study of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI), CP-358.774 in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN)
109. A phase I, dose escalation, pharmacokinetics (PK) and pharmacodynamic (PD) study of ZD1839: NCIC CTG IND.122
110. A phase I intermittent dose-escalation trial of ZD1839 (IressaTM) in Japanese patients with solid malignant tumors
111. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
112. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
113. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice
114. Development of targeted ansamycins as novel anti-steroid agents and tyrosine kinase inhibitors in the treatment of breast and prostate
115. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer
116. Phase I study of oral CEP-701, a novel neurotrophin receptor-linked tyrosine knase inhibitor
117. SU5416 and SU6668 inhibit biological functions of c-kit in a myeloid leukemia cell line and in AML blasts
118. Dose finding study of cisplatin, gem-citabine and SU5416 in patients with advanced malignancies
119. Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK)
120. A phase I/II study of repetitive dose AngiozymeTM, a ribozyme targeting the Flt-1 receptor for VEGF
121. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor
122. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
123. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status
124. Pharmacokinetics (PK) of flavopiridol IV bolus in patients with refractory neoplasms
125. Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindoyl-sulphonamide inhibiting the activation of cdk2 and cyclin E
126. Treatment of patients with metastatic melanoma with bryostatin-1: A phase II study
127. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
128. Pharmocodynamic evaluation of the protein kinase C (PKC) inhibitor CGP41251 (PKC412) in patients with metastatic melanoma
129. A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor
130. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
131. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory tumors
132. Phase I trial of a mixed backbone oligonucleotide (GEM231) antisense to protein kinase A RIalpha (PKA) with taxotere (T) in patients with advanced cancers
133. Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: Toxicity, hormonal, and immunological effects
134. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continous intravenous infusion in patients with advanced cancer
135. A novel cell cycle inhibitor (Ro 31-7453): A clinical and pharmacokinetic study in patients with solid tumors